Illumina Launches New Oncology Menu For NovaSeq X Series Customers

Illumina Launches New Oncology Menu For NovaSeq X Series Customers

By, Admin 8 August 2024

Overview

Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced it has expanded its oncology menu for NovaSeq X Series customers. The company began offering the newly verified high-throughput version of TruSight Oncology 500 (TSO 500 HT), and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months. These assays enable labs to confidently expand oncology testing research of tissue and liquid biopsy samples, with new transformative sequencing economics, faster sequencing run times, and broader batch sizes on the NovaSeq X Series for the first time.

Words from CCO: Illumina

  • We are excited to deliver customers our flagship oncology assays, now fully tested and supported on the NovaSeq X,"" said Everett Cunningham, chief commercial officer of Illumina. 
  • Empowering labs to scale distributed comprehensive genomic profiling serves to help advance the use of CGP in clinical oncology research and drive precision oncology forward.""

Comprehensive genomic profiling (CGP) assesses hundreds of genes across all variant classes, and immuno-oncology biomarkers, in a single assay from one sample to enable therapy selection research. 

CGP is increasingly included in recommended professional guidelines in oncology.

TSO 500 HT

  • TSO 500 HT on the NovaSeq X Series offers increased throughput with impactful sequencing economic improvements, as compared to the NovaSeq 6000 System. 
  • Illumina announced today that it will expand TSO 500 HT to the company's benchtop NextSeq 1000 and NextSeq 2000 Systems later this quarter.

TSO 500 ctDNA v2

  • TSO 500 ctDNA v2 on the NovaSeq X Series enables a faster, more sensitive, and streamlined liquid biopsy CGP workflow from minimally invasive blood samples for solid tumour therapy selection research, now in a fully supported and verified workflow.
  • TSO 500 ctDNA v2 offers improvements including transformative sequencing economics; faster sequencing run times by about 40%, resulting in a three-day total assay turnaround time; and more sustainable logistics, with ambient temperature shipping for consumables.

From Genomic Services at Almac Diagnostic Services

  • Laura Knight, global VP of Genomic Services at Almac Diagnostic Services, said: ""As a leader in next-generation sequencing diagnostics and research, Almac is delighted that Illumina TSO 500 ctDNAv2 is now being made available on the NovaSeq X Plus platform to enable comprehensive genomic profiling. The NovaSeq X Plus compatibility takes molecular analysis of blood-based biomarkers to new levels.""
  • With increased throughput, faster turnaround time, and optimized reagent economics, Almac can now accelerate oncology research and diagnostic development,"" Knight added. 
  • We believe that the TSO500 ctDNA v2 assay, combined with the power of NovaSeq X Plus, represents a transformative advancement in precision medicine.

About TSO 500 Portfolio

  • The TSO 500 portfolio is a research-use-only pan-cancer portfolio that enables comprehensive genomic profiling from either tissue or liquid (blood) biopsies. 
  • Designed to identify known and emerging tumour biomarkers across 523 genes, the TSO 500 portfolio utilizes both DNA and RNA (DNA only for liquid biopsy analysis) from tumour samples to identify key variants critical for cancer development and progression, such as small DNA variants (single nucleotide variants, indels), fusions, splice variants, and copy number variants. 
  • In addition, it assesses key genomic signatures, such as tumour mutational burden (TMB), microsatellite instability (MSI), and Homologous recombination deficiency (HRD).

About Illumina

  • Illumina is improving human health by unlocking the power of the genome. 
  • It focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!